INDBInternet News Database 2.5 Updated 2 min ago · 397 sources Show or hide images Light or dark

Results for “Cancer Drug”

Health
1 source

Who is covering this

India TodayCenter
Truth score 40
Centre 100%100%
India TodayCenter

Cancer drug margins rebound despite 2019 price intervention

Cancer drug margins rebound despite price intervention

Lean: Center Fact-focusedFactuality: HighCountry: IndiaFunding: CorporateOwner: Living Media
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
India100%
Media ownership
Living Media100%
Avg reliability72
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 40 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 72 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Business
1 source

Who is covering this

LivemintCenter
Truth score 34
Centre 100%100%
LivemintCenter

Cancer drugs from space? Why pharma firms are looking beyond Earth to manufacture next-gen medicines

Pharma companies are exploring space-based manufacturing to grow drug crystals in microgravity, potentially improving cancer drug formulations. Companies such as Varda and BioOrbit are testing whether orbiting laboratories can make...

Lean: Center Fact-focusedCountry: IndiaFunding: CorporateOwner: Independent
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
India100%
Media ownership
Independent100%
Avg reliability-
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 34 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: Not rated Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Health
1 source

Who is covering this

Taipei TimesCenter
Truth score 41
Centre 100%100%
Taipei TimesCenter

Legalize cancer drug fund: groups

Lean: Center Fact-focusedFactuality: HighCountry: TaiwanFunding: PrivateOwner: Liberty Times Group
Full coverage
Coverage breakdown
Funding
Private100%
Countries
Taiwan100%
Media ownership
Liberty Times Group100%
Avg reliability75
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 41 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 75 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Health
1 source

Who is covering this

CBC NewsLeans left
Truth score 451
Left 100%100%
CBC NewsLeans left

His cancer drug costs $90K/month

Drug prices are pushing public health care past the breaking point and some oncologists across Canada are blaming corporate greed. James Howard is paying $90,000 a month entirely out of pocket for a new pancreatic cancer medication from...

Lean: Leans left VideoFactuality: Very highCountry: CanadaFunding: Public broadcasterOwner: Canadian Government
Full coverage
Coverage breakdown
Funding
Public broadcaster100%
Countries
Canada100%
Media ownership
Canadian Government100%
Avg reliability85
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 45 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 85 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Left 17%17%Centre 50%50%Right 33%33%
ReutersCenter

US FDA declines to approve Summit lung cancer drug after trial misses key survival goal

(MedPage Today) -- The FDA declined to approve a closely watched drug developed in China for an indication in non-small cell lung cancer (NSCLC), drugmaker Summit Therapeutics announced, though the investigational bispecific antibody...

Lean: Center Fact-focusedFactuality: Very highCountry: United KingdomFunding: CorporateOwner: Thomson Reuters
+ 2 · Full coverage
Coverage breakdown
Funding
Corporate67%
Nonprofit17%
Private17%
Countries
United States67%
United Kingdom33%
Media ownership
Independent33%
Thomson Reuters17%
G/O Media17%
Epoch Media Group17%
Reason Foundation17%
Avg reliability66
Low-credibility share17%
Fact / opinion7/0
State media0%
More analysis
Truth score: 72 (Corroborated) Propaganda risk: 0 Trending: Low Sources: 6 Reliability: 66 Bias severity: 33 Risk: 17Sentiment: 57Sensationalism: 2 Amplification: 0

How we score

Like
Health
2 sources

Who is covering this

KFMB-TVNot ratedKHOUNot rated
Truth score 44
No rated outlets yet
KHOUNot rated

Daily Dose: Promising pancreatic cancer drug, bladder cancer in younger women, fever facts and flu season tips

An experimental drug that breaks down a tumor's protective tissue wall made pancreatic cancer disappear in 75% of treated mice.

Lean: Not rated Fact-focusedCountry: United States
Full coverage
Coverage breakdown
Funding
Not recorded100%
Countries
United States100%
Media ownership
KHOU50%
KFMB-TV50%
Avg reliability-
Low-credibility share0%
Fact / opinion2/0
State media0%
More analysis
Truth score: 44 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 2 Reliability: Not rated Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Health
1 source

Who is covering this

MedpagetodayCenter
Truth score 38
Centre 100%100%
MedpagetodayCenter

'Grand Slam' Pancreatic Cancer Drug Shows Promise as First-Line Treatment

(MedPage Today) -- The first-in-class RAS inhibitor daraxonrasib (Rasonque) in combination with chemotherapy showed promise as a first-line treatment for patients with metastatic pancreatic adenocarcinoma (PDAC), according to results...

Lean: Center Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Independent
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
Independent100%
Avg reliability65
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 38 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 65 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Science
1 source

Who is covering this

IbtimesCenter
Truth score 38
Centre 100%100%
IbtimesCenter

FDA Rejects Promising Lung Cancer Drug Despite 48% Reduction in Risk of Disease Progression or Death

The FDA has rejected Summit Therapeutics' ivonescimab lung cancer treatment, saying trial data did not sufficiently prove patients lived longer despite a 48% lower risk of progression or death.

Lean: Center Fact-focusedFactuality: Mostly factualCountry: United KingdomFunding: CorporateOwner: Independent
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United Kingdom100%
Media ownership
Independent100%
Avg reliability65
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 38 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 65 Bias severity: 0 Risk: 0Sentiment: -100Sensationalism: 0 Amplification: 0

How we score

Like
Health
1 source

Who is covering this

Times of IndiaCenter
Truth score 38
Centre 100%100%
Times of IndiaCenter

Morning Brief Podcast: The Cancer Drug Price Trap

Lean: Center Fact-focusedFactuality: Mostly factualCountry: IndiaFunding: CorporateOwner: Independent
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
India100%
Media ownership
Independent100%
Avg reliability65
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 38 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 65 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Business
1 source

Who is covering this

LivemintCenter
Truth score 34
No rated outlets yet
LivemintCenter

NPPA slashes cancer drug MRPs by up to 93%; Thiotepa cut by ₹72,921

The drug pricing regulator has slashed retail prices of 543 formulations across 137 non-scheduled cancer medicines, with some cuts exceeding 90% under a trade margin rationalisation framework. 

Lean: Center Fact-focusedCountry: IndiaFunding: CorporateOwner: Independent
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
India100%
Media ownership
Independent100%
Avg reliability-
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 34 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: Not rated Bias severity: 0 Risk: 0Sentiment: -100Sensationalism: 8 Amplification: 0

How we score

Like
Health
1 source

Who is covering this

MedscapeCenter
Truth score 38
Centre 100%100%
MedscapeCenter

How Pharmacists Decide Which Cancer Drugs Get Funded

Regulatory approval is only the starting point: Pharmacists weigh clinical benefits, safety, trial relevance, and cost when deciding whether a cancer drug merits public funding. Medscape News Europe

Lean: Center Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Independent
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
Independent100%
Avg reliability65
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 38 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 65 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Health
1 source

Who is covering this

India TodayCenter
Truth score 40
Centre 100%100%
India TodayCenter

Why India's massive cancer drugs price drop may not benefit all

Why Indias massive cancer drugs price drop may not benefit all

Lean: Center Fact-focusedFactuality: HighCountry: IndiaFunding: CorporateOwner: Living Media
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
India100%
Media ownership
Living Media100%
Avg reliability72
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 40 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 72 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 12 Amplification: 0

How we score

Like
Technology
1 source

Who is covering this

The HinduLeans left
Truth score 43
Left 100%100%
The HinduLeans left

Are lower MRPs on cancer drugs translating into affordable care?

Lean: Leans left OpinionFactuality: HighCountry: IndiaFunding: PrivateOwner: The Hindu Group
Full coverage
Coverage breakdown
Funding
Private100%
Countries
India100%
Media ownership
The Hindu Group100%
Avg reliability80
Low-credibility share0%
Fact / opinion0/1
State media0%
More analysis
Truth score: 43 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 80 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 6 Amplification: 0

How we score

Like
Business
1 source
Truth score 42
Left 100%100%
The Sydney Morning HeraldLeans left

Amplia gets nod for new cancer drug trial ahead of US push

Amplia Therapeutics has received ethics approval for its ACCENT-Mini pancreatic cancer trial, paving the way to test daily doses of its narmafotinib drug alongside chemotherapy.

Lean: Leans left Fact-focusedFactuality: HighCountry: AustraliaFunding: CorporateOwner: Nine Entertainment
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
Australia100%
Media ownership
Nine Entertainment100%
Avg reliability78
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 42 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 78 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Business
1 source
Truth score 41
Right 100%100%
South China Morning PostLeans right

Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback

Shares in Hong Kong-listed Akeso plunged as much as 31.8 per cent on Monday morning after the US Food and Drug Administration (FDA) rejected its cancer drug application, raising investor worries over the company’s near-term commercial...

Lean: Leans right Fact-focusedFactuality: HighCountry: Hong KongFunding: CorporateOwner: Alibaba Group
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
Hong Kong100%
Media ownership
Alibaba Group100%
Avg reliability75
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 41 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 75 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Technology
1 source

Who is covering this

The HinduLeans left
Truth score 43
Left 100%100%
The HinduLeans left

Comply with new prices of 137 anti-cancer drugs or face action, says regulator

NPPA directs State drug controllers to strictly monitor prices

Lean: Leans left Fact-focusedFactuality: HighCountry: IndiaFunding: PrivateOwner: The Hindu Group
Full coverage
Coverage breakdown
Funding
Private100%
Countries
India100%
Media ownership
The Hindu Group100%
Avg reliability80
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 43 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 80 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Health
1 source

Who is covering this

Fox NewsRight
Truth score 38
Right 100%100%
Fox NewsRight

Viral ‘heightmaxxing’ trend has teen boys taking cancer drugs to grow taller, doctors warn of risks

Erdafitinib, a cancer medication, is being misused by teens chasing height growth. Medical experts detail the severe risks of the heightmaxxing trend.

Lean: Right Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Fox Corporation
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
Fox Corporation100%
Avg reliability65
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 38 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 65 Bias severity: 0 Risk: 0Sentiment: 100Sensationalism: 0 Amplification: 0

How we score

Like
Health
1 source

Who is covering this

Daily ExpressLeans right
Truth score 37
Right 100%100%
Daily ExpressLeans right

Huge warning as blood pressure and cancer drugs run short

Various drugs, including Propranolol, are running low and a warning has been issued ahead of the winter months.

Lean: Leans right Fact-focusedFactuality: Mostly factualCountry: United KingdomFunding: CorporateOwner: Independent
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United Kingdom100%
Media ownership
Independent100%
Avg reliability62
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 37 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 62 Bias severity: 0 Risk: 0Sentiment: -100Sensationalism: 12 Amplification: 0

How we score

Like
Health
1 source

Who is covering this

The HinduLeans left
Truth score 43
Left 100%100%
The HinduLeans left

Sharp cuts in price of cancer drugs expose excessive pricing, say health experts

NPPA releases revised MRPs for 543 brands of anti-cancer medicines with the new prices effective from November 9; Jan Swasthya Abhiyan India (JSA India) says controlling trade margins alone is insufficient as life-saving cancer...

Lean: Leans left Fact-focusedFactuality: HighCountry: IndiaFunding: PrivateOwner: The Hindu Group
Full coverage
Coverage breakdown
Funding
Private100%
Countries
India100%
Media ownership
The Hindu Group100%
Avg reliability80
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 43 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 80 Bias severity: 0 Risk: 0Sentiment: -100Sensationalism: 0 Amplification: 0

How we score

Like
Health
1 source

Who is covering this

The HinduLeans left
Truth score 43
Left 100%100%
The HinduLeans left

Will the price caps on cancer drugs help bring down the cost of treatment?

For cancer patients in India, the struggle to stay alive is as much about the disease as about the arithmetic of fighting it. Experts call the government’s price caps a tokenistic, short-term measure. Patients will not benefit unless...

Lean: Leans left Fact-focusedFactuality: HighCountry: IndiaFunding: PrivateOwner: The Hindu Group
Full coverage
Coverage breakdown
Funding
Private100%
Countries
India100%
Media ownership
The Hindu Group100%
Avg reliability80
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 43 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 80 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 6 Amplification: 0

How we score

Like
Business
1 source

Who is covering this

The HinduLeans left
Truth score 43
Left 100%100%
The HinduLeans left

NPPA orders compliance check as trade margin cuts cancer drug prices

The national drug price regulator warned that violations of revised MRPs will invite overcharging proceedings

Lean: Leans left Fact-focusedFactuality: HighCountry: IndiaFunding: PrivateOwner: The Hindu Group
Full coverage
Coverage breakdown
Funding
Private100%
Countries
India100%
Media ownership
The Hindu Group100%
Avg reliability80
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 43 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 80 Bias severity: 0 Risk: 0Sentiment: -100Sensationalism: 8 Amplification: 0

How we score

Like
Health
1 source

Who is covering this

MedpagetodayCenter
Truth score 38
Centre 100%100%
MedpagetodayCenter

CMS Finalizes Physician Fees; Cancer Drug Crystals in Orbit; KFC Shift Curse Tested

(MedPage Today) -- Note that some links may require registration or subscription. CMS finalized its 2027 Physician Fee Schedule which aims to strengthen primary care, expand preventive services, reduce duplicate billing, and cut waste...

Lean: Center Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Independent
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
Independent100%
Avg reliability65
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 38 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 65 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Health
1 source

Who is covering this

The HinduLeans left
Truth score 43
Left 100%100%
The HinduLeans left

NPPA fixes prices of 35 drug formulations, cuts ceiling price of cancer drug oxaliplatin

In the Nov 2 notification, the drug price regulator revised the ceiling price of oxaliplatin injection, a platinum-based chemotherapy drug used to treat colorectal and other gastrointestinal cancers

Lean: Leans left Fact-focusedFactuality: HighCountry: IndiaFunding: PrivateOwner: The Hindu Group
Full coverage
Coverage breakdown
Funding
Private100%
Countries
India100%
Media ownership
The Hindu Group100%
Avg reliability80
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 43 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 80 Bias severity: 0 Risk: 0Sentiment: -100Sensationalism: 8 Amplification: 0

How we score

Like
Health
1 source

Who is covering this

The HinduLeans left
Truth score 43
Left 100%100%
The HinduLeans left

Patented, single source cancer drug prices remain unchanged under 30% margin cap, NPPA data shows

The findings raise questions about the extent to which the measure will bring down the cost of newer, patented cancer treatments.

Lean: Leans left Fact-focusedFactuality: HighCountry: IndiaFunding: PrivateOwner: The Hindu Group
Full coverage
Coverage breakdown
Funding
Private100%
Countries
India100%
Media ownership
The Hindu Group100%
Avg reliability80
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 43 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 80 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 8 Amplification: 0

How we score

Like
Health
1 source

Who is covering this

Times of IndiaCenter
Truth score 38
Centre 100%100%
Times of IndiaCenter

Morning Brief Podcast: China vs US: The New War Over Cancer Drugs and Biotech Supremacy

Lean: Center Fact-focusedFactuality: Mostly factualCountry: IndiaFunding: CorporateOwner: Independent
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
India100%
Media ownership
Independent100%
Avg reliability65
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 38 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 65 Bias severity: 0 Risk: 0Sentiment: -100Sensationalism: 0 Amplification: 0

How we score

Like
Health
1 source

Who is covering this

The HinduLeans left
Truth score 43
Left 100%100%
The HinduLeans left

For years, some cancer drugs cost up to 15 times their new price

Of the 397 brands whose price fell, 217 were at least twice as expensive as their revised price, and 120 were at least three times as expensive

Lean: Leans left Fact-focusedFactuality: HighCountry: IndiaFunding: PrivateOwner: The Hindu Group
Full coverage
Coverage breakdown
Funding
Private100%
Countries
India100%
Media ownership
The Hindu Group100%
Avg reliability80
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 43 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 80 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Health
2 sources
Truth score 54
Left 50%50%Centre 50%50%
QuartzLeans left

GSK won U.S. approval for its second lung cancer drug from the Nuvalent deal

The FDA granted accelerated approval to neladalkib, sold as Nelkarmi, for ALK-positive non-small cell lung cancer

Lean: Leans left Fact-focusedFactuality: HighCountry: United StatesFunding: CorporateOwner: G/O Media
  • Medpagetoday FDA Adds Another Player in ALK-Positive Lung Cancer

    (MedPage Today) -- The FDA granted accelerated approval to the third-generation ALK inhibitor neladalkib (Nelkarmi) for previously treated advanced ALK-positive non-small cell lung cancer (NSCLC), making it the...

    Lean: Center Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Independent
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
G/O Media50%
Independent50%
Avg reliability68
Low-credibility share0%
Fact / opinion2/0
State media0%
More analysis
Truth score: 54 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 2 Reliability: 68 Bias severity: 0 Risk: 0Sentiment: 50Sensationalism: 0 Amplification: 0

How we score

Like
Business
1 source

Who is covering this

The New York TimesLeft
Truth score 46
Left 100%100%
The New York TimesLeft

F.D.A. Rejects Closely Watched Lung Cancer Drug From China

The treatment, called ivonescimab, has become a symbol of China’s rise in drug development.

Lean: Left Fact-focusedFactuality: Very highCountry: United StatesFunding: PrivateOwner: NY Times Company
Full coverage
Coverage breakdown
Funding
Private100%
Countries
United States100%
Media ownership
NY Times Company100%
Avg reliability88
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 46 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 88 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Health
1 source

Who is covering this

MedpagetodayCenter
Truth score 38
Centre 100%100%
MedpagetodayCenter

ChatGPT Linked to Death; FDA Flags Cancer Drug Claims; AMA Fights Medicaid Rules

(MedPage Today) -- Note that some links may require registration or subscription. The parents of a 31-year-old software engineer with epilepsy who died in February sued OpenAI, claiming ChatGPT told the engineer to stop taking her...

Lean: Center Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Independent
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
Independent100%
Avg reliability65
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 38 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 65 Bias severity: 0 Risk: 0Sentiment: -100Sensationalism: 0 Amplification: 0

How we score

Like
Health
1 source

Who is covering this

ReutersCenter
Truth score 47
Centre 100%100%
ReutersCenter

Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive Q3 beat

Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive Q3 beat Reuters

Lean: Center Fact-focusedFactuality: Very highCountry: United KingdomFunding: CorporateOwner: Thomson Reuters
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United Kingdom100%
Media ownership
Thomson Reuters100%
Avg reliability92
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 47 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 92 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like